Fundraising Fox
Editas Medicine
NASDAQ: EDITCambridge, US · Founded 2013 · 9 known investors
Find your way into Editas Medicine
Sign up to see every warm intro you have to Editas Medicine
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Editas Medicine team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer. The company focuses on in vivo genome editing approaches and serves patients worldwide with transformative, precision genomic medicines.
Founders & leadership
Editas Medicine was founded in 2013 by Feng Zhang, George Church, Keith Joung, and David Liu.
Investors · 9
How we know: GV (Google Ventures)'s portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · Not right? Tell us
How we know: Viking Global's portfolio page · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$120M disclosed across 1 of 3 rounds · 1900–2015
▶$120MraisedAug 2015 · 43 investors · BiotechnologyRule 506(b)
- Katrine BosleyExecutive Officer, Director
- Vic MyerExecutive Officer
- Alexandra GlucksmannExecutive Officer
- Douglas ColeDirector
- Kevin BittermanDirector
- Andrew HackExecutive Officer
- Boris NikolicDirector
- Alexis BorisyDirector
- Offering amount
- $120M
- Amount sold
- $120M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
4 people who came through Editas Medicine went on to found or lead other companies.
Related companies · 2
Companies working in the same space as Editas Medicine.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Editas Medicine do?
- Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer. The company focuses on in vivo genome editing approaches and serves patients worldwide with transformative, precision genomic medicines.
- Who founded Editas Medicine?
- Editas Medicine was founded by Feng Zhang, George Church, Keith Joung, David Liu in 2013.
- Who are Editas Medicine's investors?
- Editas Medicine's investors include EcoR1 Capital, GV (Google Ventures), Sofinnova Ventures, Viking Global, Atlas Venture, Deerfield Management Company, Flagship Ventures, Polaris Partners and 1 more.
- How much funding has Editas Medicine raised?
- Editas Medicine has disclosed $120M raised across 1 of its 3 known rounds.
- Where is Editas Medicine headquartered?
- Editas Medicine is headquartered in Cambridge, US.